Recurrent renal cell carcinoma

clinical and prognostic value of FDG PET/CT

Pierpalolo Alongi, Maria Picchio, Fabio Zattoni, Marianna Spallino, Luigi Agostino Gianolli, Giorgio Saladini, Laura Evangelista

Research output: Contribution to journalArticle

Abstract

Purpose: The purpose of our study was 1) to evaluate the diagnostic performance of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT), 2) to assess the impact of FDG PET/CT on treatment decision-making, and 3) to estimate the prognostic value of FDG PET/CT in the restaging process among patients with renal cell carcinoma (RCC). Methods: From the FDG PET/CT databases of San Raffaele Hospital in Milan, Italy, and the Veneto Institute of Oncology in Padua, Italy, we selected 104 patients with a certain diagnosis of RCC after surgery, and for whom at least 24 months of post-surgical FDG PET/CT, clinical, and instrumental follow-up data was available. The sensitivity and specificity of FDG PET/CT were assessed by histology and/or other imaging as standard of reference. Progression-free survival (PFS) and overall survival (OS) were computed using the Kaplan–Meier method. Univariate and multivariate Cox proportional hazards models were used to identify predictors of outcome. Results: FDG PET/CT resulted in a positive diagnosis in 58 patients and a negative diagnosis in 46 patients. Sensitivity and specificity were 74 % and 80 %, respectively. FDG PET/CT findings influenced therapeutic management in 45/104 cases (43 %). After a median follow-up period of 37 months (± standard deviation 12.9), 51 (49 %) patients had recurrence of disease, and 26 (25 %) had died. In analysis of OS, positive versus negative FDG PET/CT was associated with worse cumulative survival rates over a 5-year period (19 % vs. 69 %, respectively; p

Original languageEnglish
Pages (from-to)464-473
Number of pages10
JournalEuropean Journal Of Nuclear Medicine
Volume43
Issue number3
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Renal Cell Carcinoma
Italy
Positron Emission Tomography Computed Tomography
Sensitivity and Specificity
Fluorodeoxyglucose F18
Survival Analysis
Proportional Hazards Models
Disease-Free Survival
Decision Making
Histology
Survival Rate
Databases
Recurrence
Survival
Therapeutics

Keywords

  • FDG PET/CT
  • Multivariate analysis
  • Prognosis
  • Recurrence
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Recurrent renal cell carcinoma : clinical and prognostic value of FDG PET/CT. / Alongi, Pierpalolo; Picchio, Maria; Zattoni, Fabio; Spallino, Marianna; Gianolli, Luigi Agostino; Saladini, Giorgio; Evangelista, Laura.

In: European Journal Of Nuclear Medicine, Vol. 43, No. 3, 01.03.2016, p. 464-473.

Research output: Contribution to journalArticle

@article{687e71aae76047efa168b3e516ba0023,
title = "Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT",
abstract = "Purpose: The purpose of our study was 1) to evaluate the diagnostic performance of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT), 2) to assess the impact of FDG PET/CT on treatment decision-making, and 3) to estimate the prognostic value of FDG PET/CT in the restaging process among patients with renal cell carcinoma (RCC). Methods: From the FDG PET/CT databases of San Raffaele Hospital in Milan, Italy, and the Veneto Institute of Oncology in Padua, Italy, we selected 104 patients with a certain diagnosis of RCC after surgery, and for whom at least 24 months of post-surgical FDG PET/CT, clinical, and instrumental follow-up data was available. The sensitivity and specificity of FDG PET/CT were assessed by histology and/or other imaging as standard of reference. Progression-free survival (PFS) and overall survival (OS) were computed using the Kaplan–Meier method. Univariate and multivariate Cox proportional hazards models were used to identify predictors of outcome. Results: FDG PET/CT resulted in a positive diagnosis in 58 patients and a negative diagnosis in 46 patients. Sensitivity and specificity were 74 {\%} and 80 {\%}, respectively. FDG PET/CT findings influenced therapeutic management in 45/104 cases (43 {\%}). After a median follow-up period of 37 months (± standard deviation 12.9), 51 (49 {\%}) patients had recurrence of disease, and 26 (25 {\%}) had died. In analysis of OS, positive versus negative FDG PET/CT was associated with worse cumulative survival rates over a 5-year period (19 {\%} vs. 69 {\%}, respectively; p",
keywords = "FDG PET/CT, Multivariate analysis, Prognosis, Recurrence, Renal cell carcinoma",
author = "Pierpalolo Alongi and Maria Picchio and Fabio Zattoni and Marianna Spallino and Gianolli, {Luigi Agostino} and Giorgio Saladini and Laura Evangelista",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s00259-015-3159-6",
language = "English",
volume = "43",
pages = "464--473",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "3",

}

TY - JOUR

T1 - Recurrent renal cell carcinoma

T2 - clinical and prognostic value of FDG PET/CT

AU - Alongi, Pierpalolo

AU - Picchio, Maria

AU - Zattoni, Fabio

AU - Spallino, Marianna

AU - Gianolli, Luigi Agostino

AU - Saladini, Giorgio

AU - Evangelista, Laura

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Purpose: The purpose of our study was 1) to evaluate the diagnostic performance of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT), 2) to assess the impact of FDG PET/CT on treatment decision-making, and 3) to estimate the prognostic value of FDG PET/CT in the restaging process among patients with renal cell carcinoma (RCC). Methods: From the FDG PET/CT databases of San Raffaele Hospital in Milan, Italy, and the Veneto Institute of Oncology in Padua, Italy, we selected 104 patients with a certain diagnosis of RCC after surgery, and for whom at least 24 months of post-surgical FDG PET/CT, clinical, and instrumental follow-up data was available. The sensitivity and specificity of FDG PET/CT were assessed by histology and/or other imaging as standard of reference. Progression-free survival (PFS) and overall survival (OS) were computed using the Kaplan–Meier method. Univariate and multivariate Cox proportional hazards models were used to identify predictors of outcome. Results: FDG PET/CT resulted in a positive diagnosis in 58 patients and a negative diagnosis in 46 patients. Sensitivity and specificity were 74 % and 80 %, respectively. FDG PET/CT findings influenced therapeutic management in 45/104 cases (43 %). After a median follow-up period of 37 months (± standard deviation 12.9), 51 (49 %) patients had recurrence of disease, and 26 (25 %) had died. In analysis of OS, positive versus negative FDG PET/CT was associated with worse cumulative survival rates over a 5-year period (19 % vs. 69 %, respectively; p

AB - Purpose: The purpose of our study was 1) to evaluate the diagnostic performance of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT), 2) to assess the impact of FDG PET/CT on treatment decision-making, and 3) to estimate the prognostic value of FDG PET/CT in the restaging process among patients with renal cell carcinoma (RCC). Methods: From the FDG PET/CT databases of San Raffaele Hospital in Milan, Italy, and the Veneto Institute of Oncology in Padua, Italy, we selected 104 patients with a certain diagnosis of RCC after surgery, and for whom at least 24 months of post-surgical FDG PET/CT, clinical, and instrumental follow-up data was available. The sensitivity and specificity of FDG PET/CT were assessed by histology and/or other imaging as standard of reference. Progression-free survival (PFS) and overall survival (OS) were computed using the Kaplan–Meier method. Univariate and multivariate Cox proportional hazards models were used to identify predictors of outcome. Results: FDG PET/CT resulted in a positive diagnosis in 58 patients and a negative diagnosis in 46 patients. Sensitivity and specificity were 74 % and 80 %, respectively. FDG PET/CT findings influenced therapeutic management in 45/104 cases (43 %). After a median follow-up period of 37 months (± standard deviation 12.9), 51 (49 %) patients had recurrence of disease, and 26 (25 %) had died. In analysis of OS, positive versus negative FDG PET/CT was associated with worse cumulative survival rates over a 5-year period (19 % vs. 69 %, respectively; p

KW - FDG PET/CT

KW - Multivariate analysis

KW - Prognosis

KW - Recurrence

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84956683333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956683333&partnerID=8YFLogxK

U2 - 10.1007/s00259-015-3159-6

DO - 10.1007/s00259-015-3159-6

M3 - Article

VL - 43

SP - 464

EP - 473

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 3

ER -